Prisma experts talk possible new Alzheimer’s treatment

By Andrea Kelley
Courtesy The Journal
akelley@upstatetoday.com

UPSTATE — A new treatment for Alzheimer’s disease could be on the horizon.

Results were published in late November of a three-phase trial for treatment of early-stage Alzheimer’s disease.

An 18-month study of the monoclonal antibody Lecanemab showed “moderately less decline on measures of cognition and function” than the placebo, according to the results, though it was associated with adverse events.

Prisma Health physicians Dr. Shilpa Srinivasan and Dr. John Absher met with reporters

You must be logged in to view this content.